Zaki Al Yafeai, Dr. Celeste Wu, Dr. Shafiul Alam and Alexandre Do Couto E Silva were recognized as American Heart Association Fellowship recipients.
The School of Graduate Studies offers PhD degrees in five programs, an MS degree in Biomedical Science, and a combined MD-PhD degree program. Successful applicants can enter directly into one the five programs or can enter though the Interdisciplinary Graduate Program in which students choose a mentor and program after the first semester.
The School of Graduate Studies was established as part of the LSU Medical Center (known as LSU Health Shreveport today) in 1965, with degrees offered in five basic science departments. The first class was accepted in 1974 and the first PhD degree awarded in 1978. On March 25, 2004, the Louisiana Board of Regents approved administrative separation of the School of Graduate Studies in Shreveport from the School of Graduate Studies in New Orleans. The School of Graduate Studies in Shreveport was placed under the leadership of the LSUHS Chancellor in 2004. Dr. Sandra Roerig was appointed the first Dean of the school on April 1, 2004 and served in this role until her retirement in 2017.
Graduate Studies Administration
Working with supportive faculty mentors, our students are prepared to become biomedical scientists, contributing to advances in healthcare and biotechnology, and educators, training the next generation of basic scientists, physicians and other healthcare professionals. Learn more about our Student Achievement.
Gaganpreet Kaur and Mansoureh Barzega have been awarded Malcolm-Feist Pre-Doctoral Fellowships by the Center for Cardiovascular Diseases and Sciences.
Zaki Al-Yafeai, Physiology graduate student, was recently awarded an American Heart Association Predoctoral Fellowship Award.
Congratulations to Principal Investigator Dr. David Gross for being awarded an R15 AREA grant entitled, “Chromosomal Conformation and Nuclear Organization of Heat Shock Protein Genes.” The grant provides Dr. Gross with $100,000 per year each year for three years.
Almost all deaths from prostate cancer are a result of emergence of CRPC. Scientists from our Department of Biochemistry and Molecular Biology and Feist Weiller Cancer Center have identified a key gene - eIF4G1- that is overexpressed in the majority of cases of CRPC, allowing these cancer cells to rapidly respond to androgen deprivation therapies.